(Q33987036)

English

Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

0 references

author name string

Xiang Yang Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Dong Feng Zhou

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Lian Yuan Cao

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Gui Ying Wu

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Yu Cun Shen

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1532-1538

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Effects of repeated injections of interleukin 1beta or lipopolysaccharide on the HPA axis in the newborn rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Increased prevalence of antibrain antibodies in the sera from schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Blunted cortisol response to a psychosocial stressor in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Hypothalamic-pituitary-adrenal axis function in chronic schizophrenia: association with clinical features

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Cytokines and the brain: implications for clinical psychiatry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

In vivo immunomodulatory effects of clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Psychoneuroendocrinology of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Role of the cytokines in the hypothalamic-pituitary-adrenal and gonadal axes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Schizophrenia: a neural diathesis-stress model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The role of interleukin-6 in the activation of the hypothalamo-pituitary-adrenocortical axis and brain indoleamines by endotoxin and interleukin-1 beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Decreased production of interleukin-2 (IL-2), IL-2 secreting cells and CD4+ cells in medication-free patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Dexamethasone suppression test in positive and negative schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

A molecular basis for bidirectional communication between the immune and neuroendocrine systems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Physiopharmacological interactions between stress hormones and central serotonergic systems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypothalamic-pituitary-adrenal activity during chronic central administration of interleukin-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Ethnicity greatly influences cytokine gene polymorphism distribution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of diagnosis and age on the DST: a metaanalytic approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.NPP.1300756

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33987036&oldid=2196089117"